Please assess the completion status of the following clinical trial:

Trial Title: Pentoxifylline Treatment of Acute Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Predicted Severe Acute Pancreatitis~2. Enrollment within 72 hours of diagnosis~3. Ability to give informed consent~4. Age \>17 years~Exclusion Criteria:~1. Moderate or severe congestive heart failure~2. History of seizure disorder or demyelinating disease~3. Nursing mothers~4. Pregnancy~5. History of prior tuberculosis or risk factors for tuberculosis~6. Evidence of immunosuppression (malignancy, chronic renal failure, chemotherapy within 60 days, ongoing steroid treatment\*, and HIV)- (\*the exception of prednisone use will be allowed to participate).~7. Evidence of chronic pancreatitis from history and examination (however, acute on chronic pancreatitis diagnosis is allowed)~8. Evidence of active or pending hemorrhage.~9. Paralytic ileus with vomiting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pentoxifylline (Type: EXPERIMENTAL): Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).